Trevena (NASDAQ:TRVN) Research Coverage Started at started coverage on shares of Trevena (NASDAQ:TRVNFree Report) in a research note published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Trevena Price Performance

Shares of TRVN opened at $0.58 on Friday. Trevena has a 1-year low of $0.51 and a 1-year high of $3.28. The stock has a market cap of $10.03 million, a PE ratio of -0.21 and a beta of 1.18. The company has a debt-to-equity ratio of 8.35, a current ratio of 6.41 and a quick ratio of 6.27. The firm has a fifty day moving average price of $0.66 and a 200 day moving average price of $0.69.

Trevena (NASDAQ:TRVNGet Free Report) last announced its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter. The company had revenue of $0.18 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TRVN. Jane Street Group LLC acquired a new position in Trevena in the second quarter valued at $25,000. Jump Financial LLC acquired a new position in Trevena in the third quarter valued at $27,000. Dimensional Fund Advisors LP acquired a new position in shares of Trevena during the fourth quarter worth about $40,000. Renaissance Technologies LLC increased its stake in shares of Trevena by 51.8% during the first quarter. Renaissance Technologies LLC now owns 70,532 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 24,080 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Trevena during the second quarter worth about $70,000. 4.95% of the stock is currently owned by institutional investors and hedge funds.

About Trevena

(Get Free Report)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

See Also

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.